| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36389cdf579846a37f770c664b61f7ca |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-523
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 |
| filingDate |
2019-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82a6e7f4a26d12c81582d98b69c7678c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66fc56b7863e13dac351a400736aa024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c7a2b4fda08f49146fbd286ba5b85c7 |
| publicationDate |
2021-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3833387-A1 |
| titleOfInvention |
Compositions and methods for preventing and treating virus infection |
| abstract |
Disclosed herein are bacteria-based HIV MPER vaccine candidates, as well as bacteria-based candidates for other viruses and for bacteria. The HIV vaccine candidates express MPER-derived antigens on their surfaces using Gram autotransporters. The surface-expressed MPER antigens bind several different MPER-directed anti-HIV Broadly Neutralizing Monoclonal Antibodies. When the bacteria expressing the MPER-derived antigens on their surfaces are used to immunize mice they elicit the production of sera and vaginal wash material that bind the bacteria expressing the MPER antigens. At least one of the bacteria expressing MPER-derived antigens on their surfaces elicits the production of sera with anti-HIV neutralizing activity. Killed whole cell and live Salmonella expressing the MPER derived antigens on their surfaces constitute new approaches to HIV vaccine develop that is plausible and that could ultimately yield an inexpensive, globally appropriate candidate vaccine that could be rapidly produced and deployed largely using currently available technology. |
| priorityDate |
2018-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |